非小細胞肺がん患者に対するゲフィチニブ服用開始時の患者教育システム構築の試み
スポンサーリンク
概要
- 論文の詳細を見る
Gefitinib (Iressa®), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is effective in patients with advanced non-small cell lung cancer (NSCLC). However, since interstitial lung disease, a fatal adverse event, has occurred more frequently since gefitinib came on to the market, and ISEL and SWOG 0023 examinations have not shown any significant life-extending efficacy, patients have started to feel uneasy about being treated with it. In these circumstances, in the present study, we created a system under which pharmacists can be directly involved in treatment with gefitinib and monitor for adverse events. The subjects were 98 patients with NSCLC who were treated at our hospital, and received gefitinib at a dose of 250 mg once daily. We made a leaflet describing gefitinib and a check sheet for adverse events, and using them, explained the expected adverse events to patients and monitored their conditions. Common drug-related adverse events occurring were rash (54%), pruritus (29%) and diarrhea (23%), and most were graded as mild in degree (grade 1 or 2). Interstitial lung disease was observed in 10 of the 98 patients (10.2%), but none died. Liver injury of grade 3 or 4 occurred in 25 of 92 patients (27.2%), and some patients experienced liver injury one year after the administration of gefitinib. It is therefore necessary to monitor for adverse events in the long-term, especially liver injury. In conclusion, we consider it important for pharmacists to reassure patients about gefitinib and detect the adverse events early.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)